Two Locks Apart
The bottom line: Even if the government approves the first psychedelic medicine for trauma, the drug stays officially banned for a long time after. Approval and full legal access are two separate locks, and today's signals say they will not open at the same time. For someone waiting on this treatment, that means good news and a long wait can both be true at once.
Today the swarm of forecasting agents kept circling one stubborn fact. There are two different government doors here, not one. The first is the FDA, the agency that decides whether a medicine is safe and works. The second is the DEA, the agency that controls which drugs are tightly restricted. Most of the strongest predictions today — confidence between 66 and 72 percent — point to the same thing: even if the FDA blesses MDMA for trauma, the DEA likely will not loosen its grip within the next year. The forecasters also expect the FDA to move carefully, asking for one more big study or attaching heavy safety rules before letting the medicine reach a wide audience. On the money side, the small companies in this field jumped today — Compass up nearly 5 percent, MindMed up over 4 percent — but the agents flagged this as nervous betting before the next big test result, not proof that anything has actually been settled.
Beneath the news is a quieter truth about how change really arrives. It does not come as one clean victory. It comes in stages, with the careful people in charge moving slower than the hopeful people watching. The pattern forming is a narrow first door: trauma sufferers, especially veterans, may get access first, under strict supervision, while everyone else waits much longer. That can feel like a brake. But there is another way to read it. A slow, supervised opening is the kind that lasts. The highest path here is not the fastest headline — it is the version where the first patients are kept genuinely safe, the early results hold up, and that solid record becomes the thing no one can argue with later. The forecasters even warned about a real risk: at-home ketamine treatments are growing fast without enough oversight, and one bad incident could trigger a crackdown. The most positive outcome is the field choosing care now so it does not lose trust later.
Picture the veteran who has carried trauma for fifteen years and has read every hopeful article. Today's signal asks something hard of that person: keep hoping, but hold it loosely. The treatment is coming, and the careful pace is not a betrayal — it is the thing that makes the eventual arrival real and permanent rather than a brief opening that slams shut. For the family watching a loved one struggle, the honest message is that the door is opening, just not all at once, and the part opening first may well be the part built for people in the deepest pain. That is not a small thing. It is the difference between a promise and a foundation.
The science is catching up to what the plants have always known. OOTW exists at that exact moment of convergence — the data and the mystery meeting each other.
What is being called in cannot be called back.
72%
The DEA will not change psilocybin or MDMA's illegal status this year
Even if the FDA (the US drug regulator) approves a psychedelic medicine, a completely separate agency — the DEA (the Drug Enforcement Administration) — controls whether it stays classified as a dangerous, restricted substance. These two agencies move independently, and the DEA is expected to hold its position for at least another 12 months. This matters because DEA classification determines who can legally prescribe, possess, and use a drug.
→ FDA approval and DEA approval are two separate hurdles — and the DEA isn't jumping anytime soon. Confidence: 72%
Resolves: 2027-06-22 · USA
REGULATORY
the precise call ▾
DEA remains decoupled from any FDA action and does not reschedule within 12 months.. FDA approval doesn't bind scheduling. Enforcement responsibilities and diversion concerns keep us conservative regardless of clinical momentum.
70%
The FDA will add major conditions before approving MDMA as a medicine
The FDA is likely to either demand an additional round of clinical trials before approving MDMA-assisted therapy, or grant a very narrow, heavily restricted approval with strict safety monitoring requirements. This is because trial results had problems — participants could usually tell whether they got the real drug or a placebo, which muddies the data, and long-term effectiveness hasn't been proven. For patients with PTSD (post-traumatic stress disorder), this could mean approval is delayed or access is very limited.
→ MDMA therapy may get approved, but it will come with serious strings attached that limit who can offer it and how. Confidence: 70%
Resolves: 2027-03-31 · USA
REGULATORY
the precise call ▾
FDA requires a confirmatory MDMA trial or REMS-heavy conditional approval before broad market access.. Functional unblinding and durability gaps persist. I won't approve on hype, but a narrow PTSD pathway with strict controls is defensible given suicide mortality.
71%
Congress will not vote on rescheduling psychedelics within 12 months
For a drug's legal status to change at the federal level through Congress, lawmakers have to actually bring a bill to a full vote — and that's not expected to happen in the next year. The DEA will also continue operating independently from whatever the FDA decides. This matters because without a congressional vote or DEA action, the legal landscape for psychedelic medicines stays frozen.
→ Federal law on psychedelics is almost certain to stay exactly where it is for the next 12 months. Confidence: 71%
Resolves: 2026-12-19 · USA
LEGISLATION
the precise call ▾
Federal rescheduling does not reach a floor vote within 12 months; DEA stays decoupled from FDA approval.. Consensus of 3 agents: legislator, dea_officer, fda_reviewer. 2 dissenting.
70%
A psychedelic company's stock will jump or crash more than 20% in a single day
Psychedelic biotech stocks are currently riding a wave of excitement and speculation, but that excitement isn't backed by solid, proven business results. When a major event happens — like an FDA decision or clinical trial results — the stock price tends to react violently, swinging wildly up or down in a single trading day. This kind of volatility can mean big gains or devastating losses for investors very quickly.
→ Psychedelic stocks are a rollercoaster — one piece of news in the next nine months will very likely send a major stock soaring or crashing by more than 20% in a single day. Confidence: 70%
Resolves: 2027-03-22 · USA
MARKETS
the precise call ▾
Psychedelic biotech swings >20% intraday on the next binary clinical or FDA catalyst within 9 months.. Rally is anticipatory and thin-float. No de-risked fundamentals support current levels. Binary events resolve sentiment violently in both directions.
68%
Science is advancing faster than clinics can safely standardize psychedelic treatments
Researchers are rapidly learning how psychedelics work in the brain, but that knowledge is moving faster than the ability to turn it into consistent, safe treatment guidelines for clinics. In the real world — especially with ketamine, which is already legally prescribed — outcomes vary wildly depending on who's giving the treatment and how. This gap between what scientists know and what clinicians reliably do is getting wider, not smaller.
→ We're learning how psychedelics work faster than we're learning how to use them safely and consistently — and that gap is growing. Confidence: 68%
Resolves: 2027-06-22 · Global
RESEARCH
the precise call ▾
Mechanistic research outpaces standardized clinical protocols, yielding heterogeneous real-world outcomes.. Today's basic-science signals advance understanding while real-world ketamine cohorts show uncontrolled variability. The translation gap widens, not narrows.